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Mitochondrial apoptosis: killing cancer using
the enemy within
J Lopez1 and S W G Tait*,1
1Cancer Research UK Beatson Institute, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road,
Glasgow, G61 1BD, UK
Apoptotic cell death inhibits oncogenesis at multiple stages, ranging from transformation to metastasis. Consequently, in order
for cancer to develop and progress, apoptosis must be inhibited. Cell death also plays major roles in cancer treatment, serving
as the main effector function of many anti-cancer therapies. In this review, we discuss the role of apoptosis in the development
and treatment of cancer. Specifically, we focus upon the mitochondrial pathway of apoptosis—the most commonly deregulated
form of cell death in cancer. In this process, mitochondrial outer membrane permeabilisation or MOMP represents the defining
event that irrevocably commits a cell to die. We provide an overview of how this pathway is regulated by BCL-2 family proteins
and describe ways in which cancer cells can block it. Finally, we discuss exciting new approaches aimed at specifically inducing
mitochondrial apoptosis in cancer cells, outlining their potential pitfalls, while highlighting their considerable therapeutic
promise.
Every minute of life, millions of cells in our bodies undergo a
regulated form of cell death called apoptosis. This altruistic cellular
process plays varied and essential roles in keeping us healthy, not
least in protecting us from cancer. Many oncogenic stresses,
including uncontrolled proliferation or DNA damage, trigger
apoptosis; consequently, by culling cells at risk of transformation,
apoptosis effectively prevents cancer. Apoptosis also suppresses
tumourigenesis in various other ways. For example, matrix
detachment of cells—a pre-requisite for metastatic disease—
induces a form of apoptosis called anoikis. In short, for cancer to
initiate and progress, apoptosis must be inhibited at multiple
stages. Cell death also plays key roles in the treatment of cancer.
The best way to treat cancer is to kill it; indeed many anti-cancer
therapies do this by inducing cell death through various
mechanisms. Therefore, inhibition of cell death can act as a
double-whammy that both promotes tumourigenesis and inhibits
treatment responses. Nevertheless, although inhibition of cell death
promotes cancer, tumour cells themselves often remain sensitive to
apoptosis. Indeed, cancer cells are often more sensitive to cell death
than normal tissue. As we will discuss in more detail later, this
paradox can be explained because of the inherent stresses that
tumour cells face, effectively pushing them closer to the edge.
Importantly, this can provide a therapeutic window to selectively
trigger tumour death. In this mini-review, we will discuss the role
of cell death in cancer development and treatment, specifically
focusing upon the mitochondrial pathway of apoptosis. Besides
being the most commonly deregulated type of cell death
in cancer, our understanding of mitochondrial apoptosis is
now such that novel therapies have been developed to specifically
engage mitochondrial apoptosis. Although we will restrict
our discussion to mitochondrial apoptosis, it is important to
note that other forms of programmed cell death, notably
necroptosis also exist. Unlike apoptosis, necroptosis does not
require mitochondria to execute, but it is currently unclear
whether targeting necroptosis is possible or indeed beneficial in
cancer (Tait et al, 2013). Here, in a progressive manner, we
will outline the mitochondrial apoptotic pathway, describe
how tumour cells block it and then discuss exciting new
targeted therapies that exploit mitochondrial apoptosis in cancer
treatment.
MITOCHONDRIA AND CELL DEATH—FROM ENGINE
ROOM TO EXECUTIONER
Mitochondria are essential for life, mainly owing to their role in
key biosynthetic processes such as ATP generation. Paradoxically,
in the mid-1990s, evidence emerged implicating a central role for
mitochondria in apoptotic cell death. Caspase protease activity is
essential for apoptosis; once active, caspases cleave hundreds of
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different proteins leading to rapid cell death with distinctive
biochemical and morphological hallmarks (Taylor et al, 2008). In
general terms, caspase activity can be initiated either via cell-
surface death-receptors—the so-called death receptor or extrinsic
pathway (reviewed in Dickens et al (2012)) or through the
mitochondrial, also called intrinsic, pathway of apoptosis (Tait and
Green, 2010). Most stimuli induce apoptosis via the mitochondrial
pathway; in this process, the defining event is mitochondrial outer
membrane permeabilisation or MOMP. Following MOMP,
mitochondrial intermembrane space proteins, notably cytochrome
c, are released into the cytosol whereupon they activate caspases. In
mitochondrial ATP generation, cytochrome c has an essential
day-job, shuttling electrons between complexes III and IV of the
electron transport chain. However, once released from mitochon-
dria, cytochrome c adopts a lethal function that is essential for
caspase activation. Once in the cytosol, cytochrome c binds the
adaptor molecule APAF-1; this leads to extensive conformational
changes in APAF-1, causing it to oligomerise and form a
heptameric structure called the apoptosome. The apoptosome
recruits and activates pro-caspase-9 that in turn cleaves and
activates the executioner caspases-3 and -7. Executioner caspase
activity effectively kills the cell within minutes through the parallel
cleavage of hundreds of different substrates. Besides cytochrome c,
mitochondria release a variety of other proteins that promote
caspase activity following MOMP—these include SMAC (also
called Diablo) and Omi (also called HtrA2). By antagonising an
endogenous inhibitor of caspase function called XIAP, Smac and
Omi facilitate caspase activity. Importantly, MOMP often leads to
cell death irrespective of caspase activity (Tait et al, 2014). This
alternate, caspase-independent form of cell death most likely
relates to the extensive nature of MOMP such that often all mito-
chondria undergo permeabilisation leading to a progressive and
overwhelming loss of mitochondrial function (Lartigue et al, 2009).
Because MOMP effectively represents a point-of-no-return, it is
highly regulated, largely by members of the BCL-2 protein family.
This family can be sub-divided into pro-apoptotic effector proteins
(BAX and BAK), pro-apoptotic BH3-only proteins (BID, BIM,
PUMA, Noxa, HRK, BIK, BMF, BAD) and anti-apoptotic BCL-2
proteins (BCL-2, BCL-xL, MCL-1, A1, BCL-B, BCL-w) (Figure 1).
Active BAX or BAK are required to permeabilise the mitochondrial
outer membrane, although how they achieve this remains
contentious. Most often, BAX or BAK activation requires direct
interaction with a member of the BH3-only protein family. This
causes BAX and BAK conformational changes, leading to their
oligomerisation within the mitochondrial outer membrane. Some-
how, BAX or BAK oligomers permeabilise the mitochondrial outer
membrane, possibly indirectly by inducing lipid pores or,
alternatively, by directly forming pores themselves. BH3-only
proteins act as stress sentinels that relay the diverse array of
apoptotic signals towards mitochondria and MOMP via BAX/BAK
activation. Importantly, the BH3-only protein family can be sub-
divided into activators—able to directly activate BAX/BAK or
sensitisers—that neutralise the apoptotic brake offered by anti-
apoptotic BCL-2 proteins. Most drugs that mimic BH3-only
proteins (called BH3 mimetics) phenocopy sensitiser proteins.
Counteracting BAX and BAK activity are the anti-apoptotic BCL-2
proteins. These prevent MOMP and apoptosis by binding BH3-
only proteins (preventing their interaction with BAX and BAK) or
by binding activated BAX or BAK. Pro- and anti-apoptotic BCL-2
protein interactions are mediated between BH3 domains (present
on BH3-only proteins and activated BAX or BAK) and the
hydrophobic BH3-binding cleft in anti-apoptotic BCL-2 proteins.
Competitive disruption of these interactions, leading to sensitisa-
tion or induction of apoptosis, forms the basis of BH3 mimetic
biological activity. It is also important to note that BCL-2 proteins
also have roles in non-apoptotic cellular processes, for example,
calcium homeostasis (Bonneau et al, 2013).
EVADING APOPTOSIS: HOW CANCER CELLS DODGE THE
BULLET
Cancer cells use an abundant array of means to inhibit
mitochondrial apoptosis. As we will discuss now, these can be
divided into mechanisms that either prevent MOMP or inhibit
caspase function downstream of MOMP (Figure 1).
Failing to pull the trigger—inhibiting mitochondrial permeabi-
lisation. Cancer cells often block apoptosis by upregulating anti-
apoptotic BCL-2 proteins thereby preventing MOMP. Indeed, the
gene encoding BCL-2 was first identified at a chromosomal
translocation breakpoint that places BCL-2 under immunoglobulin
heavy chain enhancer transcriptional control, leading to constitu-
tively high BCL-2 expression (Tsujimoto et al, 1984). BCL-2
expression in itself is not oncogenic but dramatically enhances
tumour onset in combination with growth-promoting oncogenes
(Strasser et al, 1990). Extending these findings, many studies have
shown that the upregulation of anti-apoptotic BCL-2 proteins is a
feature common to diverse cancers. Mechanisms of upregulation
are varied but include copy number amplification, transcriptional
upregulation (driven by oncogenic signalling) or downregulation of
microRNAs that suppress anti-apoptotic BCL-2 protein expression
(Garzon et al, 2009; Beroukhim et al, 2010). Certain anti-apoptotic
BCL-2 family members, notably MCL-1, are unstable and targeted
for proteasome-dependent degradation; accordingly, mechanisms
stabilising MCL-1 (thereby enhancing its anti-apoptotic activity)
have also been described in cancer (Wertz et al, 2011).
Cancer cells have also developed a variety of means to disable
the trigger that engages cell death. A classic example is the
widespread loss of p53 tumour suppressor function seen across the
tumour spectrum. p53 has multiple effector functions one of which
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Figure 1. Execution of mitochondrial apoptosis and escape
mechanisms. Apoptotic stresses promote accumulation of BH3-only
proteins leading to BAX/BAK oligomerisation, MOMP and release of
intermembrane space proteins. Cytochrome c leads to apoptosome
formation, which results in caspase activation and apoptosis. Smac and
Omi neutralise the caspase inhibitor XIAP. Various strategies to escape
apoptosis either by inhibiting MOMP or caspases are presented in red.
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is to induce apoptosis through the upregulation of BH3-only
proteins, notably PUMA. Accordingly, the loss of p53 prevents
DNA-damage-induced apoptosis in some cell types (Clarke et al,
1993; Lowe et al, 1993). Fortunately, DNA damage triggered by
chemo- or radiotherapy can also elicit p53-independent apoptosis.
Genomic loss of the key apoptotic effectors BAX or BAK has also
been observed in a variety of cancer types. Although mouse
knockout studies suggest that these two proteins have largely
redundant functions, recent work argues that the loss of either
protein in the context of activating BH3-only protein or anti-
apoptotic BCL-2 repertoire results in a strict apoptotic dependence
for either BAX or BAK (Wang and Youle, 2012; Sarosiek et al,
2013). Besides inhibiting BAX or BAK function, the loss of various
pro-apoptotic BH3-only proteins including NOXA, PUMA and
BIM has also been documented in various tumours either by
deletion or through promoter methylation leading to transcrip-
tional silencing.
Putting the bullet back in the gun—blocking caspase function.
Cancer cells also inhibit caspase function following MOMP
(Figure 1). From our earlier discussion, this may appear futile
given that MOMP is generally considered a point of no return.
However, cells can survive MOMP in some circumstances;
although best described in post-mitotic cells such as neurons, the
ability of tumour cells to undergo MOMP and proliferate has also
been reported (Martinou et al, 1999; Deshmukh et al, 2000; Putcha
et al, 2000; Colell et al, 2007). Survival under these conditions
requires caspase inhibition and a source of intact mitochondria—in
line with this requirement, MOMP is not always complete such
that some mitochondria can remain intact (Tait et al, 2010). Cells
inhibit caspase function through various means. These include
downregulating apoptosome activity by epigenetic silencing or
inhibitory phosphorylation of APAF-1. Additionally, cytochrome c
itself can be targeted for ubiquitination and proteasome-dependent
degradation following MOMP, thereby nullifying its pro-apoptotic
activities (Gama et al, 2014). Caspase function can be directly
inhibited by XIAP or indirectly by c-IAP1 or c-IAP2 through their
ability to bind and neutralise the XIAP inhibitors SMAC and Omi.
Clearly, various means exist that allow cells to effectively nullify
caspase activity. Nevertheless, defining the occurrence of cancer
cell recovery from MOMP in vivo and understanding its impact
on tumourigenesis and treatment outcome requires further
investigation.
HARNESSING THE HITMAN: USING APOPTOSIS TO KILL
CANCER
The realisation that apoptosis is a programmed process that
requires specific proteins paved the way to directly target cell death
in cancer. Many conventional anti-cancer therapies induce
apoptosis, albeit in indirect ways. However, our extensive
molecular understanding of apoptosis gained over the last 20
years has led to the development of various drugs that directly kill
cancer cells through apoptosis. These include death-receptor
ligands, notably TRAIL, that trigger the extrinsic apoptotic
pathway and SMAC-mimetics, that were designed to enhance
caspase activation (Fulda and Vucic, 2012; Lemke et al, 2014). We
will focus our discussion on extensive efforts aimed to trigger
mitochondrial apoptosis in cancer cells by targeting the BCL-2
protein family.
Cancer cells and their suicidal tendencies. How can tumours be
selectively killed via mitochondrial apoptosis? As alluded to earlier,
based on the necessity to evade apoptosis during oncogenesis, a
common misconception is that tumours are inherently apoptosis
resistant. Often this is not the case, indeed the opposite can hold
true, cancer cells are frequently more sensitive than normal tissue
to therapy-induced apoptosis. The reasons for this are varied, but
include oncogenic stress (that are often inherently apoptotic) and
environmental stresses such as hypoxia or low-nutrient availability
that cancers often face. Irrespective of source, such stresses increase
the sensitivity of cancer cells (relative to normal, healthy cells) to
undergo MOMP and die—cells in this state have been termed as
being ‘primed for death’ (Certo et al, 2006) (Figure 2). The basis of
priming revolves around levels of pro-apoptotic BH3-only and
anti-apoptotic BCL-2 proteins. Importantly, the extent of priming
can be revealed by a technique called BH3 profiling (Certo et al,
2006). Using BH3 peptides derived from different BH3-only
proteins, this technique not only estimates the extent of cell
priming in a tumour but also gives an indication of the BCL-2
family proteins on which it requires to survive. Primed cells have
higher pro-apoptotic BH3-only protein loads that, through
necessity, require higher anti-apoptotic BCL-2 levels to ensure
survival (Figure 2). In this way, primed cells are addicted to anti-
apoptotic BCL-2 function. In practical terms, this means that
primed cancer cells are closer to the edge such that an additional
pro-apoptotic stress—for example, chemo- or radiotherapy—can
kill these cells more readily than non-primed tissue. Additionally,
the extent of priming in healthy tissue also dictates dose-limiting
toxicities of anti-cancer therapies. Underscoring the clinical
importance of priming, different studies have shown that the
extent of tumour cell apoptotic priming correlates with therapeutic
responses and clinical prognosis (Ni Chonghaile et al, 2011; Vo
et al, 2012). In addition to dictating the sensitivity of normal and
tumour cells to conventional anti-cancer therapies, priming also
dictates the efficacy of new therapies that directly target MOMP
through the BCL-2 protein family.
Exploiting an addiction: drugging the BCL-2 family. Most
strategies to directly engage MOMP in cancer treatment have
centred upon blocking anti-apoptotic BCL-2 function—the
rationale being that this should either directly trigger apoptosis
or sensitise to an additional pro-apoptotic therapy (e.g., radio-
therapy). Developing drugs that target anti-apoptotic BCL-2
function is challenging, not least because it entails developing an
inhibitor of protein–protein interactions that targets a shallow-
hydrophobic groove. Nevertheless, effective and specific inhibitors
of BCL-2 proteins have been developed, initially using a high-
throughput NMR-based screen to identify chemical fragments that
bound the hydrophobic BH3-binding groove of BCL-xL
(Oltersdorf et al, 2005). Chemical coupling of binding fragments
to generate high-affinity ligands led to the development of ABT-
737, the prototypic BH3 mimetic that displays sub-nanomolar
affinity for BCL-xL (Oltersdorf et al, 2005). ABT-737 and ABT-263
(its more-soluble clinically applicable analogue) both display
binding profiles similar to the BH3-only protein BAD, such that
they bind BCL-xL, BCL-2 but not MCL-1. In a variety of cell and
animal models, ABT-737 and ABT-263 exhibit potent anti-
tumour activity either as single agents or in combination therapy
(Oltersdorf et al, 2005; Tse et al, 2008). Unfortunately, the clinical
application of ABT-263 is limited because it induces thrombo-
cytopenia (Tse et al, 2008; Josefsson et al, 2011). This on-target
effect is due to BCL-xL neutralisation on aged platelets leading to
their apoptotic death. To circumvent this problem, a BH3
mimetic specifically targeting BCL-2 has been developed—this
compound, ABT-199, was generated through structure-guided
chemical modification of ABT-263 (Souers et al, 2013). Attesting
to its on-target potency, initial administration of ABT-199 in
chronic lymphocyte leukaemia (CLL) was shown to cause
tumour lysis syndrome through massive induction of apoptosis
(Ng and Davids, 2014). Step-wise dose escalation should
ameliorate this problem and initial clinical trials of ABT-199
use in the treatment of CLL look promising with many patients
displaying responses.
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Cancer cells’ lust for life: BH3 mimetic resistance mechanisms.
As with all targeted therapies, resistance—either pre-existing or
acquired—presents a considerable challenge to the use of BH3
mimetics in cancer therapy (Figure 3). Considering the rapid
effects of BH3 mimetics on MOMP induction coupled with it often
being a point-of-no-return, acquired resistance to BH3 mimetics
is perhaps difficult to envision. Nevertheless, a recent report
demonstrated acquired resistance to the BCL-2-specific mimetic
ABT-199 in two different experimental lymphoma models; one
was due to an inactivating mutation in BAX, whereas the other was
a BCL-2 mutation that curiously ablated its inhibition by ABT-199
whilst maintaining anti-apoptotic activity (Fresquet et al, 2014).
Currently utilised BH3 mimetics face various, formidable intrinsic
mechanisms of resistance. One of the biggest is the current lack of
effective inhibitors targeting all anti-apoptotic BCL-2 proteins,
notably MCL-1. Although not an issue in some cancers, including
CLL and acute myeloid leukaemia that display a strict dependence
on BCL-2 for survival, it is likely to be critical in other cancers,
particularly heterogenous solid tumours. Indeed, various studies
have shown that MCL-1 expression allows cells to resist ABT-737
or ABT-263 treatment (van Delft et al, 2006). Nevertheless,
effective inhibitors of MCL-1 and possibly other, currently non-
targetable BCL-2 family members are likely to be developed soon,
providing the opportunity to neutralise the whole anti-apoptotic
BCL-2 family. At first take, this may seem desirable, maximising
the sensitisation of cancer cells to death. However, broad
neutralisation may elicit intolerable toxicity; besides the thrombo-
cytopenia caused by BCL-xL inhibition, loss of MCL-1 function
shows a variety of toxic effects in mice—though it is important to
note that effects of transient pharmacological inhibition does not
equate to irreversible loss of MCL-1 function induced in these mice
(Thomas et al, 2013; Wang et al, 2013). Additionally, various
studies argue that existing BH3 mimetics display differential
potency for targeting one BCL-2 protein vs another and between
targeting specific BH3-only/BCL-2 complexes (Aranovich et al,
2012; Merino et al, 2012; Rooswinkel et al, 2012). In the latter
example, ABT-737 effectively inhibits the BH3-only proteins BAD
and BID from binding BCL-2 but is ineffective at preventing Bim
from binding. Whether this holds true for clinically applicable BH3
mimetics is not known, but if so, it implies that these drugs may be
less effective in tumours that require BCL-2 to neutralise BIM.
Although often overlooked in experimental systems, the tumour
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microenvironment can massively affect cellular sensitivity to BH3
mimetics. For example, CLL cells resident in the lymph nodes are
much more resistant to apoptosis than circulating ones. Mimicking
the lymph node stromal and cytokine environment in vitro leads to
a massive upregulation of different anti-apoptotic Bcl-2 proteins,
including A1 (also called BFL-1) that is not inhibited by existing
BH3 mimetics. Consequently, this renders CLL cells effectively
resistant to ABT-737 (Vogler et al, 2009). The microenvironment
can also affect BH3-mimetic sensitivity in other ways. For example,
levels of pro-apoptotic NOXA are reduced, whereas anti-apoptotic
MCL-1 levels are increased in lymph node vs peripheral CLL,
thereby promoting BH3-mimetic resistance in lymph node-
resident CLL (Smit et al, 2007). Importantly, survival signalling
by the TNF receptor family member CD40 that causes this
deregulated NOXA/MCL-1 balance can be targeted thereby
restoring cell death sensitivity (Hallaert et al, 2008). Another
major means of cancer cell resistance to BH3-mimetic therapy is
that cells simply are not primed. As discussed earlier, current BH3
mimetics mimic sensitiser BH3-only proteins in that they inhibit
anti-apoptotic BCL-2 function. This in itself is insufficient to
trigger apoptosis and an additional stimulus to activate BAX or
BAK and MOMP is required. An obvious way to provide this is
through a second apoptosis-engaging chemotherapy or radio-
therapy. Alternatively, BH3 mimetics that mimic direct activator
BH3-only proteins and trigger apoptosis could be developed. Along
these lines, potent small molecular activators of BAX have been
developed (Gavathiotis et al, 2012). With both approaches
(combination therapy or BAX/BAK activators), a significant
concern is that these will cause unacceptable toxicity in healthy
tissue. However, one would still predict that increased priming of
cancer cells would make them more sensitive, potentially offering a
therapeutic window.
SUMMARY
As discussed, fantastic advances have been made over the last 20
years in our understanding of the mitochondrial apoptotic pathway
and its role in cancer. The development and clinical application of
BH3-mimetic drugs that specifically target mitochondrial apoptosis
in cancer is a watershed moment. Nevertheless, many challenges
remain, not least extending the utility of targeting mitochondrial
apoptosis to diverse tumour types as well as circumventing
mechanisms of resistance. Moreover, similar to conventional
cancer therapies, it is clear that BH3-mimetic therapy also entails
walking a therapeutic tightrope—balancing maximal tumour cell
death vs tolerable toxicities. These points notwithstanding, we
anticipate that clinical application of existing and the development
of novel approaches to directly target the mitochondrial apoptotic
pathway will prove highly effective in cancer treatment.
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